Company Overview
Arcus Biosciences, Inc. operates as a clinical-stage biopharmaceutical entity focused on the development and commercialization of cancer therapies specifically within the United States market. The company functions within the Healthcare sector and the Biotechnology industry, positioning itself to advance novel treatments such as Casdatifan, a HIF-2a inhibitor for kidney cancer, and Domvanalimab, an anti-TIGIT antibody. In terms of scale, the organization commands a market capitalization of $2.71B while generating annual revenue of $247.00M and maintaining an employee base of 601. The combination of a $2.71B market cap and $247.00M in revenue indicates that the company has established a significant presence in the biotechnology landscape, yet the negative gross margin suggests that its current financial model relies heavily on future commercialization milestones rather than immediate profitability from existing sales.
Financial Health
The company reported a revenue of $247.00M over the trailing twelve months, yet this figure masks a substantial net income loss of $-353,000,000 and an EBITDA of $-376,000,000, revealing a cost structure where expenses significantly exceed top-line generation. This divergence between revenue and net income highlights a deep burn rate typical of clinical-stage biopharmaceutical firms investing heavily in research, development, and clinical trial operations. Free cash flow stands at $-162,250,000, indicating that the company is consuming cash reserves to fund its growth initiatives and operational expenditures rather than generating surplus liquidity. Despite this consumption, the balance sheet retains $981.00M in cash against $219.00M in debt, supported by a debt-to-equity ratio of 34.71 which suggests a leveraged position reliant on equity financing rather than excessive debt burden. Liquidity is robust with a current ratio of 4.36, indicating that current assets are more than four times the value of current liabilities, providing ample buffer for short-term obligations. However, return metrics reflect the high-risk nature of the business, with a return on equity of -63.3% and a return on assets of -21.1%, demonstrating that management has not yet achieved positive returns on invested capital or equity.
Valuation Assessment
Valuation multiples for the company are distorted by its lack of profitability, as the P/E Ratio (TTM) is listed as N/A and the Forward P/E is -6.20, implying that traditional earnings-based valuation models are not applicable due to negative earnings expectations. The price-to-book ratio of 4.30 indicates that the market values the company at a significant premium over its book value, reflecting high expectations for the future success of its drug portfolio. Alternative valuation metrics such as the price-to-sales ratio of 10.98 and an EV/EBITDA of -5.19 further illustrate that investors are pricing in future growth potential rather than current operational performance. Regarding price action, the stock has traded between a 52-week low of $6.50 and a 52-week high of $26.40, meaning the current valuation sits within a range that has seen substantial volatility but remains below its recent peak. The stock exhibits a beta of 0.92, suggesting that its price volatility moves in tandem with the broader market, lacking the extreme sensitivity often seen in small-cap biotechnology firms.
Growth & Income
Revenue growth for the trailing twelve months is recorded at 26.9%, whereas earnings growth is listed as N/A due to the company's continued losses, indicating that revenue expansion is outpacing any potential for immediate earnings generation. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available earnings and cash flow are directed back into the business to fund clinical trials and operational scaling. This strategy prioritizes reinvestment into growth initiatives rather than returning capital to shareholders, a common approach for clinical-stage biopharmaceutical companies aiming to reach market approval for their therapies. Overall, the growth and income profile is characterized by strong top-line expansion coupled with significant cash burn and no current income distribution to investors.